The US Food and Drug Administration said 1 February it will share information about manufacturing deficiencies identified in remote records reviews conducted in lieu of or in advance of pre-approval and pre-license inspections and will consider sponsors’ responses to the findings.
The agency may later expand the policy to include records reviews conducted in lieu of or in advance of surveillance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?